UA129533C2 - Функціональний репортерний гібридний білок та спосіб визначення активності нейротоксину с. botulinum (bont) in vitro і in vivo - Google Patents

Функціональний репортерний гібридний білок та спосіб визначення активності нейротоксину с. botulinum (bont) in vitro і in vivo Download PDF

Info

Publication number
UA129533C2
UA129533C2 UAA201905231A UAA201905231A UA129533C2 UA 129533 C2 UA129533 C2 UA 129533C2 UA A201905231 A UAA201905231 A UA A201905231A UA A201905231 A UAA201905231 A UA A201905231A UA 129533 C2 UA129533 C2 UA 129533C2
Authority
UA
Ukraine
Prior art keywords
luciferase
protein
neurotoxin
chain polypeptide
cleavage site
Prior art date
Application number
UAA201905231A
Other languages
English (en)
Ukrainian (uk)
Inventor
Мінь Дун
Минь ДУН
Фейфань Юй
Original Assignee
Презідент Енд Феллоуз Оф Гарвард Колледж
Президент Энд Феллоуз Оф Гарвард Колледж
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Презідент Енд Феллоуз Оф Гарвард Колледж, Президент Энд Феллоуз Оф Гарвард Колледж filed Critical Презідент Енд Феллоуз Оф Гарвард Колледж
Publication of UA129533C2 publication Critical patent/UA129533C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0069Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
UAA201905231A 2016-10-20 2017-10-19 Функціональний репортерний гібридний білок та спосіб визначення активності нейротоксину с. botulinum (bont) in vitro і in vivo UA129533C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662410558P 2016-10-20 2016-10-20
PCT/US2017/057411 WO2018075783A2 (en) 2016-10-20 2017-10-19 In vitro and cell based assays for measuring the activity of botulinum neurotoxins

Publications (1)

Publication Number Publication Date
UA129533C2 true UA129533C2 (uk) 2025-05-28

Family

ID=60413254

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201905231A UA129533C2 (uk) 2016-10-20 2017-10-19 Функціональний репортерний гібридний білок та спосіб визначення активності нейротоксину с. botulinum (bont) in vitro і in vivo

Country Status (21)

Country Link
US (2) US11306347B2 (https=)
EP (1) EP3529616B1 (https=)
JP (2) JP7227901B2 (https=)
KR (1) KR102556363B1 (https=)
CN (1) CN110088624B (https=)
AU (1) AU2017345560C1 (https=)
BR (1) BR112019007831A2 (https=)
CA (1) CA3040507A1 (https=)
DK (1) DK3529616T5 (https=)
EA (1) EA039761B1 (https=)
ES (1) ES2963830T3 (https=)
FI (1) FI3529616T3 (https=)
HU (1) HUE064332T2 (https=)
MX (2) MX2019004431A (https=)
PL (1) PL3529616T3 (https=)
PT (1) PT3529616T (https=)
SA (1) SA519401607B1 (https=)
SG (1) SG11201903523YA (https=)
UA (1) UA129533C2 (https=)
WO (1) WO2018075783A2 (https=)
ZA (1) ZA201902654B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2825370A1 (en) 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
WO2015134121A2 (en) 2014-01-20 2015-09-11 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
WO2016077052A2 (en) 2014-10-22 2016-05-19 President And Fellows Of Harvard College Evolution of proteases
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
SG11201809903WA (en) * 2016-05-16 2018-12-28 Harvard College Method for purification and activation of botulinum neurotoxin
WO2018075783A2 (en) 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
US12060553B2 (en) 2017-08-25 2024-08-13 President And Fellows Of Harvard College Evolution of BoNT peptidases
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
US20220259269A1 (en) * 2019-07-15 2022-08-18 President And Fellows Of Harvard College Evolved botulinum neurotoxins and uses thereof
WO2021195479A1 (en) * 2020-03-26 2021-09-30 Cellex, Inc. Protease assays and their applications
CN114540419A (zh) * 2022-03-04 2022-05-27 中国人民解放军军事科学院军事医学研究院 一种分析包膜病毒膜融合效率的三功能报告系统
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
EP4700040A1 (en) * 2023-04-21 2026-02-25 Shenzhen Loggene Life Science & Technology Co., Ltd. Peptide and luminescent complex containing same
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay
KR20250158928A (ko) * 2024-04-30 2025-11-07 주식회사 바이오링크스 앵커 단백질을 이용한 미광성 세포기반의 보툴리눔 독소의 검출 및 활성 평가방법
KR20260002179A (ko) * 2024-06-28 2026-01-06 ㈜바이오솔빅스 Snap-25를 발현하는 운동신경세포 제조 방법 및 제조된 운동신경세포를 이용한 보툴리눔 신경독소 역가 측정 방법
CN119039432B (zh) * 2024-10-31 2025-01-28 兰州生物技术开发有限公司 一种检测肉毒毒素活性或突触体相关蛋白的方法和试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4950588A (en) 1985-07-10 1990-08-21 Molecular Diagnostics, Inc. Prolonged enhanced chemiluminescence
DE3537877A1 (de) 1985-10-24 1987-04-30 Geiger Reinhard Luciferin-derivate und immunoassays unter einsatz derartiger luciferin-derivate
US5004565A (en) 1986-07-17 1991-04-02 The Board Of Governors Of Wayne State University Method and compositions providing enhanced chemiluminescence from 1,2-dioxetanes
US5374534A (en) 1990-07-19 1994-12-20 Charm Sciences, Inc. Method of preparing D-luciferin derivatives
DE4210759A1 (de) 1992-04-01 1993-10-07 Boehringer Mannheim Gmbh Substituierte Thiazolin-Dioxetan-Substrate, Verfahren zur Herstellung und Verwendung
JP3523879B2 (ja) 1994-05-31 2004-04-26 アレルガン インコーポレイテッド 輸送タンパク質用クロストリジウム属細菌毒素の修飾
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
JP2002507410A (ja) 1998-03-27 2002-03-12 プロルーム・リミテッド ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
US6890745B1 (en) 2000-07-19 2005-05-10 Chemicon International, Inc. Protease specific cleavable luciferases and methods of use thereof
CA2541765A1 (en) * 2003-10-10 2004-10-01 Promega Corporation Luciferase biosensor
US8753831B2 (en) 2007-06-05 2014-06-17 City Of Hope Methods for detection of botulinum neurotoxin
LT3409764T (lt) 2009-05-01 2020-06-10 Promega Corporation Sintetinės oplophorus liuciferazės su sustiprinta šviesos išeiga
US20140287433A1 (en) * 2011-07-19 2014-09-25 ETH Zürich Means and methods for determining clostridial neurotoxins
CA2866595A1 (en) 2012-03-07 2013-09-12 Merz Pharma Gmbh & Co. Kgaa Means and methods for determining neurotoxin activity based on a modified luciferase
CA2886939C (en) * 2012-10-16 2020-11-03 Merz Pharma Gmbh & Co. Kgaa Cellular test systems for the determination of the biological activities of neurotoxin polypeptides
KR20150087321A (ko) * 2012-11-21 2015-07-29 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소 생물학적 활성의 결정을 위한 수단 및 방법
SG11201507306VA (en) 2013-03-15 2015-10-29 Promega Corp Activation of bioluminescence by structural complementation
AU2014301116B2 (en) * 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
PT3274364T (pt) * 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
WO2018075783A2 (en) 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
EP3893916A4 (en) * 2018-12-11 2023-03-29 Q32 Bio Inc. FUSION PROTEIN CONSTRUCTS FOR A COMPLEMENT-ASSOCIATED DISEASE

Also Published As

Publication number Publication date
PL3529616T3 (pl) 2024-03-18
ZA201902654B (en) 2024-08-28
JP7227901B2 (ja) 2023-02-22
US20220356508A1 (en) 2022-11-10
AU2017345560A1 (en) 2019-05-02
EP3529616A2 (en) 2019-08-28
EP3529616B1 (en) 2023-09-06
AU2017345560B2 (en) 2024-12-12
SG11201903523YA (en) 2019-05-30
KR102556363B1 (ko) 2023-07-18
MX2019004431A (es) 2019-08-14
HUE064332T2 (hu) 2024-03-28
DK3529616T3 (da) 2023-12-11
SA519401607B1 (ar) 2022-08-04
KR20190068582A (ko) 2019-06-18
EA039761B1 (ru) 2022-03-10
FI3529616T3 (fi) 2023-12-04
DK3529616T5 (da) 2024-09-02
MX2023004733A (es) 2023-05-10
WO2018075783A2 (en) 2018-04-26
ES2963830T3 (es) 2024-04-02
EA201990929A1 (ru) 2019-10-31
US11306347B2 (en) 2022-04-19
CA3040507A1 (en) 2018-04-26
CN110088624B (zh) 2024-01-16
CN110088624A (zh) 2019-08-02
AU2017345560C1 (en) 2025-04-17
US11788069B2 (en) 2023-10-17
JP2019532651A (ja) 2019-11-14
JP2023011700A (ja) 2023-01-24
BR112019007831A2 (pt) 2019-10-01
US20190276873A1 (en) 2019-09-12
PT3529616T (pt) 2023-12-06
WO2018075783A3 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
UA129533C2 (uk) Функціональний репортерний гібридний білок та спосіб визначення активності нейротоксину с. botulinum (bont) in vitro і in vivo
US11020435B2 (en) Functionalized erythroid cells
US12590138B2 (en) Treatments administering chimeric IgG Fc receptor comprising an extracellular domain of CD64
Aït-Ali et al. Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis
CN105792840B (zh) 细胞
JP5837917B2 (ja) エーリキア・カニスの免疫反応性糖タンパク質gp19
JP7427208B2 (ja) 視覚機能再生剤又は視覚機能低下予防剤
UA127308C2 (uk) Активована протеазою біспецифічна молекула, яка зв'язує т-клітини
AU2015308243A1 (en) Signalling system
US20180037632A1 (en) Compositions and Methods for Diagnosis and Treatment of Cancer
US11267874B2 (en) Sensor systems for target ligands and uses thereof
CN114133450B (zh) 抗-Rho GTPase的构象单域抗体及其用途
JPH08500737A (ja) グルカゴン・レセプタ
CN101160321A (zh) Q3 sparc缺失突变体及其用途
CN117777297B (zh) 抗内源性pink1蛋白的单克隆抗体及其应用
CN101643511B (zh) 抑制端粒酶活性的融合蛋白、其制备及应用
UA120584C2 (uk) Варіантний інсектицидний ген axmi115 та способи його застосування
Hu et al. The Arg233Lys AQP0 mutation disturbs aquaporin0-calmodulin interaction causing polymorphic congenital cataract
WO2021146487A2 (en) Il2 orthologs and methods of use
JP2021518428A (ja) プログラム可能な免疫細胞受容体複合体システム
JP2023527026A (ja) 強化された合成t細胞受容体及び抗原受容体
CN109311950A (zh) 用于抑制wnt信号传导的组合物和方法
JPWO2012029958A1 (ja) 新たに同定したインスリン分泌制御因子を用いた抗糖尿病薬剤のスクリーニング法
CN120457202A (zh) 触发诱导型mRNA环化
CA3153342A1 (en) Methods of engineering platelets for targeting circulating tumor cells